Status:
COMPLETED
RPE Characterisation With Transscleral Optical Phase Imaging in Retinal Disorders
Lead Sponsor:
Luzerner Kantonsspital
Conditions:
Retinal Disease
Eye Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Accumulating evidence suggest that the functional unit of photoreceptor/ retinal pigment epithelium (RPE)/Bruch's membrane/choriocapillaris plays a key role in pathophysiologic processes of a wide ran...
Eligibility Criteria
Inclusion
- Informed Consent as documented by signature (Appendix Informed Consent Form)
- Patients with a medical retinal disease involving the retinal pigment epithelium (age related macular degeneration, diabetic retinopathy, retinal vascular occlusive disease, central serous chorioretinopathy, tapetoretinal degeneration)
- Participants with healthy eyes for the control group
Exclusion
- Inability to follow the procedures of the study due to language problems, psychological disorders, dementia etc. of the participant
- Aged \< 18 years.
- Pregnancy
- Epilepsy
Key Trial Info
Start Date :
May 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT04912622
Start Date
May 19 2021
End Date
October 31 2022
Last Update
March 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital Luzern
Lucerne, Switzerland